Hormone therapy in transgender adults is safe with provider supervision; A review of hormone therapy sequelae for transgender individuals

被引：128

作者：

Weinand, Jamie D. ^{[1
]}

Safer, Joshua D. ^{[1
]}

机构：

[1] Boston Univ, Sch Med, Sect Endocrinol Diabet & Nutr, Transgender Med Res Grp, 715 Albany St,Room M-1016, Boston, MA 02118 USA

来源：

JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY | 2015年 / 2卷 / 02期

关键词：

Transgender; Transsexual; Hormone therapy; Safety; Review;

D O I：

10.1016/j.jcte.2015.02.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: Some providers report concern for the safety of transgender hormone therapy (HT). Methods: This is a systematic literature review of HT safety for transgender adults. Results: Current literature suggests HT is safe when followed carefully for certain risks. The greatest health concern for HT in transgender women is venous thromboembolism. HT among transgender men appears to cause polycythemia. Both groups experienced elevated fasting glucose. There is no increase in cancer prevalence or mortality due to transgender HT. Conclusion: Although current data support the safety of transgender HT with physician supervision, larger, long-term studies are needed in transgender medicine. (C) 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license

引用

页码：55 / 60

页数：6

共 72 条

[1]

[Anonymous], 2014, JOINT M INT SOC END

[2] MORTALITY AND MORBIDITY IN TRANSSEXUAL PATIENTS WITH CROSS-GENDER HORMONE-TREATMENT [J].